Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and raises the price target f...
Avenue Therapeutics, Inc. (OTC:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on...
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous syst...
Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and raises the price target...
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the pri...
RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and raises the price targe...
Wells Fargo analyst Benjamin Burnett maintains Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and lowers the price targ...
Guggenheim analyst Yatin Suneja maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $200...
Needham analyst Ami Fadia reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $154 price target.
